Discussion with the Medical Products Agency regarding the risk RA population
We have developed a Regulatory briefing book in RTCure. This has informed our regulatory discussions, identifying key issues such as the identification of unmet need, well-defined criteria to identifying patients at risk, and care pathway analysis with information on costs of early intervention vs potential savings to the society would be required. This document was the basis of initial discussion with the Swedish Medical Products Agency. Read it here!